State Biotech Policy

Kimball Thomson, President & CEO of BioUtah discusses his organization and what makes Utah a good place for innovative industry growth.

The 2012 BIO International Convention featured a broad array of top-level speakers, addressing critical global challenges and the top issues in biotechnology. Hosted by the Biotechnology Industry Organization (BIO), the event drew 16,505 industry leaders from 65 countries.

Bioscience economic development in a nation as large and diverse as the United States is as varied as the country itself.  A complex array of factors influence the allocation of resources and the nature of bioscience industry development.

At a time when the global economy struggles to recover from a severe recession and uncertainty remains regarding future economic growth, bioscience industry development is generating significant attention both globally and at home.

Bob Coughlin discusses the elements of supportive bioscience industry climates and looks ahead to the 2012 BIO International Convention.

State governments in 2011 continued to see regional economic growth in the life sciences industry and in 2012 will increasingly focus attention on technology transfer and venture funding as mechanisms to increase private sector innovation related activities within their jurisdictions. Realizing that entrepreneurship is a key ingredient in economic development, states and localities are undertaking the support of programs that assist high technology businesses, and that capitalize on state regional presence of universities and federal laboratories.

The 2011 BIO International Convention brought together over 15,000 leaders from industry, government and academia who are working to solve some of the sector's biggest challenges. We were honored to host governors from 11 U.S. states as they promote their bioscience economic development endeavors.

New Orleans shows the signs of a city reborn from the destruction brought on by Hurricane Katrina.  The changes in the city’s infrastructure and building projects have certainly been among them.  The city reached a  milestone its renaissance when the New Orleans BioInnovation Center (NOBIC) opened for business.

In this global economy, nearly every competitor has access to big breakthroughs in technology and to the equipment and capital to produce standardized products, but those regions that possess the human capital, with its insights, competencies, and experience will have the competitive advantage.

Pete Pellerito discusses what is being done to provide the workforce for this broad and growing industry.

Tracy Cooley talks to Renee Winsky about biotech in Maryland and the upcoming  BIO International Convention  in Washington, DC.

Despite the fact that U.S. Secretary of Agriculture Tom Vilsack believes that the regulation of genetically engineered agricultural products must be science-based, and that he has “no doubts about the safety of the products this system has approved and will continue to approve,” some state legislatures are considering bills requiring labeling for biotech-derived food. These bills defy existing science-based regulation and are wholly unnecessary.

You might have heard that the Prince of Wales, just days after hosting the Royal Wedding, paid us a visit here in Washington.  Prince Charles, a long-time organic food advocate and self-described environmentalist, was here to speak at a Washington Post symposium on the Future of Food.

January 31 2014
Dear Ms. Badrov:   The Biotechnology Industry Organization (BIO) and the Illinois Biotechnology Industry Organization (iBIO) appreciate this opportunity to comment on the Illinois Department of Healthcare and Family Services (the “Department”) proposed rule to amend 89 Ill. Adm. Code 140 regarding the 340B Drug Discount Program (the “Proposed Rule”).    BIO is the largest trade association to serve and represent the biotechnology industry in the United States and around the globe.  Indeed, BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers, and related organizations.   BIO members are involved in the research and development of healthcare, agricultural, industrial, and environmental biotechnology products.  In Illinois BIO works in collaboration with iBIO, whose membership includes strong representation from the bio-pharmaceutical sector.  This sector accounts for a large portion of the $98 billion in biotech annual economic output and 369,000 directly and indirectly-created jobs in the state.  
January 31 2014
Dear Ms. Gibson: To Whom It May Concern: The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the Texas Health and Human Services Commission (HHSC) proposed rule regarding 340B program reimbursement (the “Proposed Rule”).  BIO is the largest trade association to serve and represent the biotechnology industry in the United States and around the globe.  Indeed, BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers, and related organizations.   BIO members are involved in the research and development of healthcare, agricultural, industrial, and environmental biotechnology products. 
January 21 2014
BIO's Senior Policy Consultant, Peter Pellerito, testified before the Michigan Legislature's Bioscience Caucus on economic development initiatives that support the growth of the bioscience industry.
May 8 2013
BIO  urges Florida Governor Scott to sign House Bill 365 – a bill related to the substitution of biologic and biosimilar medicines – which recently passed out of the Legislature.
February 1 2013
BIO supports passage of Florida House Bill 365, which provides requirements for pharmacist to dispense substitute biological products that are determined to be interchangeable for prescribed biological product.
April 10 2014
BIO and Delaware Bio commend the Delaware State Senate for unanimously passing legislation yesterday designed to create a pathway for the substitution of interchangeable biologic medicines. 
April 9 2014
The House Subcommittee on Capital Markets and Government Sponsored Enterprises held a hearing titled “Legislative Proposals to Enhance Capital Formation for Small and Emerging Growth Companies.” Brian Hahn, Chief Financial Officer of GlycoMimetics, Inc. presented testimony at the hearing on enhancements to the capital markets that can increase access to investors and decrease unnecessary regulatory burdens for emerging biotech companies trading on the public market.
January 30 2014
Patients Should Be Informed if Doctor's Prescription Changed
January 22 2014
BIO and WBBA commend the Washington State House and Senate for continuing to advance legislation designed to create a pathway for the substitution of interchangeable biologic medicines.
November 13 2013
The Pennsylvania Senate Public Health and Welfare Committee approved Senate Bill 405, which would require a pharmacist to notify the patient and, within 72 hours, the patient’s physician of any biologic product substitution.